Dual inhibitors of tim-3 and pd-1 pathways

Abstract

The present disclosure relates to 3-substituted 1,2,4-oxadiazole compounds and their derivatives, which are useful as T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) inhibitors or as dual inhibitors of TIM-3 and the programmed cell death 1 (PD-1) signaling pathway. The disclosure also relates to treatment of disorders by inhibiting an immunosuppressive signal induced by TIM-3, PD-1, PD-L1, and/or PD-L2.

1 - 85 . (canceled) 
     
     
         86 . A method of modulating an immune response mediated by T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) activity in a subject, comprising administering to the subject a compound, wherein the compound is 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof. 
     
     
         87 . The method of  claim 86 , wherein the compound is 
       
         
           
           
               
               
           
         
       
     
     
         88 . The method of  claim 86 , wherein the compound is a pharmaceutically acceptable salt of 
       
         
           
           
               
               
           
         
       
     
     
         89 . The method of  claim 86 , wherein the immune response is further mediated by the programmed cell death 1 (PD-1) signaling pathway. 
     
     
         90 . The method of  claim 86 , wherein the immune response is further mediated by an agent that modulates TIM-3. 
     
     
         91 . The method of  claim 86 , wherein the subject is suffering from a disease or disorder selected from cancer, an immune disorder, an immunodeficiency disorder, an inflammatory disorder, an infectious disease, and transplant rejection; and the method treats the disease or disorder. 
     
     
         92 . The method of  claim 91 , wherein the disease or disorder is cancer. 
     
     
         93 . The method of  claim 92 , wherein the cancer is selected from breast cancer, colon cancer, liver cancer, ovarian cancer, prostate cancer, renal cancer, and uterine cancer. 
     
     
         94 . The method of  claim 92 , wherein the cancer is selected a hematopoietic cancer. 
     
     
         95 . The method of  claim 94 , wherein the hematopoietic cancer is selected from lymphoma, B cell lymophoma, T cell lymphoma, Burkitt's lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, a leukemia, a myeloma, acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myelogenous leukemia (CML), chronic lymphoblastic leukemia (CLL), chronic myelomonocytic leukemia (CMML), multiple myeloma, myelodysplastic syndrome (MDS), and plasmacytoma. 
     
     
         96 . The method of  claim 92 , wherein the cancer is selected from ovarian cancer, colon cancer, breast cancer, lung cancer, a myeloma, a neuroblastic-derived CNS tumor, a monocytic leukemia, a B-cell derived leukemia, a T-cell derived leukemia, a B-cell derived lymphoma, a T-cell derived lymphoma, and a mast cell derived tumor. 
     
     
         97 . The method of  claim 92 , wherein the cancer is selected from blastoma, breast cancer, epithelial cancer, colon cancer, lung cancer, melanoma, prostate cancer, renal cancer, bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, uterine cancer, ovarian cancer, colorectal cancer, rectal cancer, cancer of the anal region, cancer of the peritoneum, connective tissue cancer, eye cancer. throat cancer, oral cavity cancer, biliary tract cancer, stomach cancer, testicular cancer, carcinoma of the fallopian tubes, endometrial cancer, cervical cancer, vaginal cancer, vulval cancer, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, thyroid cancer, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma, cancer of the urethra, cancer of the penis, chronic or acute leukemia, acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), myeloproliferative disorder/neoplasm (MPDS), myelodysplasia syndrome, a monocytic leukemia, a B-cell derived leukemia, a T-cell derived leukemia, solid tumors of childhood, a B-cell derived lymophoma, T-cell dervied lymphoma, Hodgkin's lymphoma, indolent and aggressive non-Hodgkin's lymphoma, Burkitt's lymphoma, follicular lymphoma, mesothelioma, thymic carcinoma, myeloma, multiple myeloma, giant cell myeloma, heavy-chain myeloma, light chain or Bence-Jones myeloma, a mast cell derived tumor, leiomyoma, leiomyosarcoma, glioma, cancer of the bladder, cancer of the ureter, carcinoma of the renal pelvis, liver cancer, pancreatic cancer, post-transplant lymphoproliferative disorder (PTLD), neuroblastic-derived CNS tumors, neoplasm of the central nervous system (CNS), tumor angiogenesis, spinal axis tumor, brain stem glioma, pituitary adenoma, epidermoid cancer, salivary gland carcinoma, squamous cell cancer, abnormal vascular proliferation associated with phakomatoses, Meigs' syndrome, Merkel cell carcinoma, and environmentally induced cancers. 
     
     
         98 . The method of  claim 91 , wherein the disease or disorder is an immune disorder, immunodeficiency disorder, or an inflammatory disease. 
     
     
         99 . The method of  claim 87 , wherein the immune response is further mediated by the programmed cell death 1 (PD-1) signaling pathway. 
     
     
         100 . The method of  claim 87 , wherein the immune response is further mediated by an agent that modulates TIM-3. 
     
     
         101 . The method of  claim 88 , wherein the immune response is further mediated by the programmed cell death 1 (PD-1) signaling pathway. 
     
     
         102 . The method of  claim 88 , wherein the immune response is further mediated by an agent that modulates TIM-3.